PMGC Holdings Announces 1-for-4 Reverse Stock Split, Reducing Shares to 508,721
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy ELAB?
Source: Newsfilter
- Reverse Stock Split Implementation: PMGC Holdings will execute a 1-for-4 reverse stock split on January 6, 2026, reducing the outstanding shares to approximately 508,721, which is expected to enhance the per-share price and improve market appeal.
- Impact on Shareholders: All shareholders will see their shares adjusted proportionally, ensuring that the overall value of equity remains unchanged, as every four shares will consolidate into one, simplifying the capital structure.
- Trading Symbol Remains Unchanged: While the CUSIP number will be updated to 73017P409, the trading symbol
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAB
About ELAB
PMGC Holdings Inc. is a management, advisory, and investment company specializing in United States (U.S.)-based opportunities across financial services, manufacturing, and healthcare. Its segments include corporate, treasury and biosciences, IT packaging solutions and precision engineering and machining. The Company's portfolio consists of various subsidiaries: Northstrive BioSciences Inc., PMGC Research Inc., PMGC Capital LLC, Pacific Sun Packaging Inc. and AGA Precision Systems LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is focused on advancing the frontiers of scientific discovery. AGA Precision Systems LLC specializes in CNC machining operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GB Capital Advises PMGC on SVM Acquisition
- Acquisition Overview: PMGC Holdings Inc. completed the acquisition of 100% of SVM Machining, Inc. on February 2, 2026, executed on a cash-free, debt-free basis, aiming to build a U.S. precision manufacturing platform through the integration of profitable, high-quality businesses.
- Advisory Role: GB Capital served as co-advisor to PMGC, leading the financial due diligence process, which included quality of earnings analysis, working capital assessment, and preparation of historical financial statements to ensure compliance with U.S. GAAP audit requirements.
- Post-Closing Support: GB Capital will also provide post-closing transition and integration services, implementing its proprietary C.O.R.E. Financial Framework™ to standardize accounting, reporting, and internal controls, ensuring PMGC's financial reporting meets audit readiness standards.
- Company Background: GB Capital Ltd. is a strategic finance, advisory, and management firm focused on growth-stage and publicly listed companies, offering comprehensive M&A advisory, capital markets strategy, and financial reporting support to help businesses build scalable financial infrastructure.
See More
PMGC Holdings Subsidiary Signs Exclusive License Agreement
- Stock Surge: PMGC Holdings Inc. (ELAB) shares surged nearly 45% in pre-market trading on Wednesday, reflecting strong market optimism regarding the company's growth potential following the signing of a new agreement.
- Exclusive License Agreement: The company's wholly-owned subsidiary, NorthStrive Biosciences, signed an exclusive license agreement with Modulant Biosciences, granting Modulant the rights to develop, manufacture, and commercialize products using NorthStrive's EL-22 and EL-32 assets, which is expected to drive revenue growth.
- Bullish Market Sentiment: Following the announcement, retail sentiment around PMGC Holdings trended into 'bullish' territory, with message volumes at 'high' levels, indicating a significant increase in investor confidence in the company's future performance.
- Commercialization Opportunities: This agreement not only provides Modulant with the opportunity to develop new products but also has the potential to generate ongoing royalty revenue for PMGC, thereby enhancing its market competitiveness and financial stability.
See More
NorthStrive Signs Exclusive License Agreement with Modulant for Animal Health Products
- License Agreement Signed: NorthStrive has executed an exclusive license agreement with Modulant covering the EL-22 and EL-32 assets, allowing Modulant to develop and commercialize non-human animal health products globally, marking a significant advancement for the company in the animal health market.
- Technological Application Outlook: The EL-22 and EL-32 assets target key biological regulators of muscle development and metabolic efficiency, which are expected to enhance livestock productivity and feed efficiency, addressing the growing demand for animal health solutions and potentially increasing the company's market share in this sector.
- Clear Development Responsibilities: Under the agreement, Modulant is responsible for all development, manufacturing, and commercialization activities, ensuring compliance with regulatory and quality standards in the animal health field, thereby enhancing NorthStrive's competitive position in the market.
- Strategic Implications: The signing of this agreement not only converts the previously announced term sheet into a definitive agreement but also provides a clear framework for NorthStrive's product development and commercialization efforts in the animal health sector, positioning the company favorably in a rapidly growing market.
See More
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
See More
PMGC Holdings Stock Declines Following AI Program Update
- AI Program Update: PMGC Holdings has announced that the results from Phase III of its AI Development Program are now expected in Q2 2026, extending the timeline and potentially impacting future performance.
- Acquisition of SVM Machining: PMGC has completed the acquisition of SVM Machining for $2.25 million, enhancing its precision manufacturing capabilities in medical and aerospace sectors, with SVM projected to generate $3.04 million in revenue for 2024.
- Stock Price Trends: PMGC's stock is currently trading 54.9% below its 20-day simple moving average and 89.8% below its 100-day SMA, indicating a bearish trend with a 99.02% decline over the past year.
- Technical Indicator Signals: Despite the bearish market sentiment, the RSI at 17.48 suggests the stock may be undervalued, while the MACD indicates a potential bullish reversal, highlighting mixed signals in the stock's momentum.
See More
NorthStrive Biosciences Provides Update on AI Development Program
- Phase III Update: NorthStrive Biosciences, in partnership with Yuva Biosciences, has updated the anticipated completion timeline for Phase III to Q2 2026, extending the original 6 to 9 weeks due to the introduction of advanced sixth-generation classifier models, which will enhance the reliability and comprehensiveness of the study results.
- Technological Advancement: The sixth-generation classifier models introduced by Yuva Biosciences significantly improve screening accuracy and sensitivity, aiding in the more precise selection of candidate compounds during the in-vitro validation stage, thereby strengthening the foundation for downstream development efforts.
- Market Potential: NorthStrive's lead asset, EL-22, utilizes an engineered probiotic approach to address the challenge of preserving muscle in obesity patients undergoing weight loss treatments, and as the AI development program progresses, it is expected to further enhance its market competitiveness.
- Corporate Strategy: PMGC Holdings, the parent company of NorthStrive, is committed to expanding its biopharmaceutical business through strategic acquisitions and investments, and will continue to focus on collaboration with Yuva Biosciences to drive innovation and growth.
See More
GB Capital Advises PMGC on SVM Acquisition
- Acquisition Overview: PMGC Holdings Inc. completed the acquisition of 100% of SVM Machining, Inc. on February 2, 2026, executed on a cash-free, debt-free basis, aiming to build a U.S. precision manufacturing platform through the integration of profitable, high-quality businesses.
- Advisory Role: GB Capital served as co-advisor to PMGC, leading the financial due diligence process, which included quality of earnings analysis, working capital assessment, and preparation of historical financial statements to ensure compliance with U.S. GAAP audit requirements.
- Post-Closing Support: GB Capital will also provide post-closing transition and integration services, implementing its proprietary C.O.R.E. Financial Framework™ to standardize accounting, reporting, and internal controls, ensuring PMGC's financial reporting meets audit readiness standards.
- Company Background: GB Capital Ltd. is a strategic finance, advisory, and management firm focused on growth-stage and publicly listed companies, offering comprehensive M&A advisory, capital markets strategy, and financial reporting support to help businesses build scalable financial infrastructure.
See More
PMGC Holdings Subsidiary Signs Exclusive License Agreement
- Stock Surge: PMGC Holdings Inc. (ELAB) shares surged nearly 45% in pre-market trading on Wednesday, reflecting strong market optimism regarding the company's growth potential following the signing of a new agreement.
- Exclusive License Agreement: The company's wholly-owned subsidiary, NorthStrive Biosciences, signed an exclusive license agreement with Modulant Biosciences, granting Modulant the rights to develop, manufacture, and commercialize products using NorthStrive's EL-22 and EL-32 assets, which is expected to drive revenue growth.
- Bullish Market Sentiment: Following the announcement, retail sentiment around PMGC Holdings trended into 'bullish' territory, with message volumes at 'high' levels, indicating a significant increase in investor confidence in the company's future performance.
- Commercialization Opportunities: This agreement not only provides Modulant with the opportunity to develop new products but also has the potential to generate ongoing royalty revenue for PMGC, thereby enhancing its market competitiveness and financial stability.
See More
NorthStrive Signs Exclusive License Agreement with Modulant for Animal Health Products
- License Agreement Signed: NorthStrive has executed an exclusive license agreement with Modulant covering the EL-22 and EL-32 assets, allowing Modulant to develop and commercialize non-human animal health products globally, marking a significant advancement for the company in the animal health market.
- Technological Application Outlook: The EL-22 and EL-32 assets target key biological regulators of muscle development and metabolic efficiency, which are expected to enhance livestock productivity and feed efficiency, addressing the growing demand for animal health solutions and potentially increasing the company's market share in this sector.
- Clear Development Responsibilities: Under the agreement, Modulant is responsible for all development, manufacturing, and commercialization activities, ensuring compliance with regulatory and quality standards in the animal health field, thereby enhancing NorthStrive's competitive position in the market.
- Strategic Implications: The signing of this agreement not only converts the previously announced term sheet into a definitive agreement but also provides a clear framework for NorthStrive's product development and commercialization efforts in the animal health sector, positioning the company favorably in a rapidly growing market.
See More
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
See More
PMGC Holdings Stock Declines Following AI Program Update
- AI Program Update: PMGC Holdings has announced that the results from Phase III of its AI Development Program are now expected in Q2 2026, extending the timeline and potentially impacting future performance.
- Acquisition of SVM Machining: PMGC has completed the acquisition of SVM Machining for $2.25 million, enhancing its precision manufacturing capabilities in medical and aerospace sectors, with SVM projected to generate $3.04 million in revenue for 2024.
- Stock Price Trends: PMGC's stock is currently trading 54.9% below its 20-day simple moving average and 89.8% below its 100-day SMA, indicating a bearish trend with a 99.02% decline over the past year.
- Technical Indicator Signals: Despite the bearish market sentiment, the RSI at 17.48 suggests the stock may be undervalued, while the MACD indicates a potential bullish reversal, highlighting mixed signals in the stock's momentum.
See More
NorthStrive Biosciences Provides Update on AI Development Program
- Phase III Update: NorthStrive Biosciences, in partnership with Yuva Biosciences, has updated the anticipated completion timeline for Phase III to Q2 2026, extending the original 6 to 9 weeks due to the introduction of advanced sixth-generation classifier models, which will enhance the reliability and comprehensiveness of the study results.
- Technological Advancement: The sixth-generation classifier models introduced by Yuva Biosciences significantly improve screening accuracy and sensitivity, aiding in the more precise selection of candidate compounds during the in-vitro validation stage, thereby strengthening the foundation for downstream development efforts.
- Market Potential: NorthStrive's lead asset, EL-22, utilizes an engineered probiotic approach to address the challenge of preserving muscle in obesity patients undergoing weight loss treatments, and as the AI development program progresses, it is expected to further enhance its market competitiveness.
- Corporate Strategy: PMGC Holdings, the parent company of NorthStrive, is committed to expanding its biopharmaceutical business through strategic acquisitions and investments, and will continue to focus on collaboration with Yuva Biosciences to drive innovation and growth.
See More
